1. Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle.
- Author
-
Chai, Ilean, Kornyeyev, Dmytro, Hsieh, Edward, Magombedze, Gesham, Stapleton, Lance, Hung, Magdeleine, Kwon, Hyock Joo, Stefanutti, Erin, Belzile, JeanPhilippe, Czerwieniec, Gregg, Wang, Adele Y., Morar, Mariya, and Lad, Latesh
- Subjects
LIFE cycles (Biology) ,PROGRAMMED cell death 1 receptors ,DIMERIZATION ,SMALL molecules ,CELL death ,BINDING sites ,PROTEINS - Abstract
The programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint blockade is central to Immuno-Oncology based therapies, and alternatives to antibody blockers of this interaction are an active area of research due to antibody related toxicities. Recently, small molecule compounds that induce PD-L1 dimerization and occlusion of PD-1 binding site have been identified and developed for clinical trials. This mechanism invokes an oligomeric state of PD-L1 not observed in cells previously, as PD-L1 is generally believed to function as a monomer. Therefore, understanding the cellular lifecycle of the induced PD-L1 dimer is of keen interest. Our report describes a moderate but consistent increase in the PD-L1 rate of degradation observed upon protein dimerization as compared to the monomer counterpart. This subtle change, while not resolved by measuring total PD-L1 cellular levels by western blotting, triggered investigations of the overall protein distribution across various cellular compartments. We show that PD-L1 dimerization does not lead to rapid internalization of neither transfected nor endogenously expressed protein forms. Instead, evidence is presented that dimerization results in retention of PD-L1 intracellularly, which concomitantly correlates with its reduction on the cell surface. Therefore, the obtained data for the first time points to the ability of small molecules to induce dimerization of the newly synthesized PD-L1 in addition to the protein already present on the plasma membrane. Overall, this work serves to improve our understanding of this important target on a molecular level in order to guide advances in drug development. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF